N/A
Manufactured by Ajanta Pharma USA Inc.
11,238 FDA adverse event reports analyzed
Last updated: 2026-04-15
ENTACAPONE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Ajanta Pharma USA Inc.. The most commonly reported adverse reactions for ENTACAPONE include DYSKINESIA, HALLUCINATION, FALL, DRUG INEFFECTIVE, DEATH. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ENTACAPONE.
Out of 3,955 classified reports for ENTACAPONE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 11,238 FDA FAERS reports that mention ENTACAPONE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DYSKINESIA, HALLUCINATION, FALL, DRUG INEFFECTIVE, DEATH, PARKINSON^S DISEASE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Ajanta Pharma USA Inc. in connection with ENTACAPONE. Always verify the specific product and NDC with your pharmacist.